Bank Julius Baer & Co. Ltd, Zurich Arcus Biosciences, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$31.38 - $48.47 $125,520 - $193,880	-4,000 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$26.93 - $37.68 $430,691 - $602,616	-15,993 Reduced 79.99%	4,000 $139,000
Q2 2021 Jul 23, 2021	BUY	$22.75 - $35.77 $454,840 - $715,149	19,993 New	19,993 $549,000
Q1 2021 May 10, 2021	SELL	$26.16 - $41.39 $385,938 - $610,626	-14,753 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$17.0 - $32.36 $189,958 - $361,590	11,174 Added 312.21%	14,753 $383,000
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $380,290 - $723,893	-22,370 Reduced 86.21%	3,579 $383,000
Q3 2020 Nov 10, 2020	BUY	$17.14 - $25.47 $114,820 - $170,623	6,699 Added 34.8%	25,949 $445,000
Q2 2020 Aug 12, 2020	SELL	$13.97 - $36.56 $272,401 - $712,883	-19,499 Reduced 50.32%	19,250 $467,000
Q1 2020 May 13, 2020	BUY	$8.78 - $19.28 $340,216 - $747,080	38,749 New	38,749 $538,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.